title: Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma.
abstract: The prognosis of myasthenia gravis (MG) in association with invasive or metastatic thymoma is usually worse, and therapeutic options are quite limited. Here, we retrospectively reported the therapeutic effect of docetaxel plus cisplatin (docetaxel/cisplatin) chemotherapy in 7 MG patients with metastatic thymoma. Previously, all patients underwent thymectomy at the first onset of thymoma. After the metastasis of thymoma, none of the patients received thymectomy due to unresectable conditions after surgeon's evaluation for great risk of myasthenic crisis (n = 5) or patients' refusal (n = 2). All patients received docetaxel (75 mg/m2) and cisplatin (70 mg/m2) on day 1 (d1) every 21 days, with the cycle ranging from 1 to 4. After docetaxel/cisplatin chemotherapy, one patient achieved partial response, and 6 with stable disease of the tumors. The clinical symptoms of MG were alleviated in all patients, 2 with complete remission and the other 5 with marked improvement. Myelosuppression was the major adverse event, occurring in 2 patients (grade II and IV). MG relapse occurred in one patient during the follow-up. Our study presented a series of MG patients with metastatic thymoma who underwent docetaxel/cisplatin chemotherapy. Besides the improved/stabilized thymoma, markedly improvement of MG with the tolerable adverse events was achieved. Docetaxel/cisplatin chemotherapy appears to be an effective treatment for selected patients with MG in association with unresectable metastatic thymoma. Further follow-up of these patients and additional subjects will be needed to determine whether the therapeutic benefits are durable.
authors.affiliation: Myasthenia Gravis Treatment Center of Hebei Province, First Hospital of Shijiazhuang.
authors.forename: Guoyan
authors.initials: G
authors.lastname: Qi
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Huimin
authors.initials: H
authors.lastname: Dong
authors.forename: Shanshan
authors.initials: S
authors.lastname: Gu
authors.forename: Hongxia
authors.initials: H
authors.lastname: Yang
authors.forename: Yinping
authors.initials: Y
authors.lastname: Xue
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D013945:Thymoma / Q000188:drug therapy* / Q000556:secondary*; D013953:Thymus Neoplasms / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin